{"entity":{"id":"nct07271355","kind":"trial","name":"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases,","aka":[],"tldr":"A phase 3 trial of bevacizumab (glioblastoma use), fluorouracil (5-FU), irinotecan (and liposomal irinotecan), leucovorin (folinic acid) and other drugs in colorectal cancer, run by City of Hope Medical Center, not yet recruiting.","summary":"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial is a phase 3, randomised interventional study registered as NCT07271355 by City of Hope Medical Center, with a registry enrolment figure of 129 participants, started 2026-10-01 and due to reach its primary completion in 2031-02-28. Interventions recorded: Bevacizumab; Biopsy Procedure; Biospecimen Collection; Computed Tomography; Fluorouracil; Irinotecan Hydrochloride; Leucovorin Calcium; Magnetic Resonance Imaging; Mitomycin; Questionnaire Administration. Conditions listed: Metastatic Appendix Carcinoma; Metastatic Colorectal Carcinoma; Metastatic Malignant Neoplasm in the Peritoneum; Stage IV Appendix Carcinoma AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Unresectable Colorectal Carcinoma. Primary outcome: Overall survival (OS). Colorectal eligibility wording from the registry: \"* Histologically or cytologically confirmed appendiceal or colorectal cancer peritoneal metastases\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07271355","url":"https://clinicaltrials.gov/study/NCT07271355"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","hipec","topoisomerase-inhibitors"],"targets":[],"drugs":["bevacizumab-glioma","fluorouracil","irinotecan","leucovorin","mitomycin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07271355","phase":"3","setting":"Investigation of Mitomycin C PIPAC - FOLFIRI Combination for Unresectable Appendiceal or Colorectal Peritoneal Metastases Treatment (IMPACT): A Multicenter, Randomized, Open-Label, Phase 3 Trial","sponsor":"City of Hope Medical Center","enrolled":129,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07271355/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"hipec","kind":"technology","name":"HIPEC / PIPAC (intraperitoneal chemotherapy)","route":"/technologies/hipec/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"irinotecan","kind":"drug","name":"Irinotecan (and liposomal irinotecan)","route":"/drugs/irinotecan/"},{"id":"leucovorin","kind":"drug","name":"Leucovorin (folinic acid)","route":"/drugs/leucovorin/"},{"id":"mitomycin","kind":"drug","name":"Mitomycin C","route":"/drugs/mitomycin/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}